There is an error in Table 7-8 in the 3rd Edition of Hemostasis
and Thrombosis (Editors.- Colman, Hirsh, Marder, and Salzman)
published in 1994 by Lippincott- Raven on the treatment of
von Willebrand disease. In the column labeled "Therapy", Humate
P was omitted as the factor VIII/von Willebrand factor (FVIII/vWF)
concentrate. This led to misalignment of the dosing recommendations
in the table and the potential for confusion between desmopressin
(DDAVP) and FVIII/vWF dosing. The proper dose of desmopressin
is 0.3 micrograms/kilogram body weight administered intravenously
diluted in sterile physiologic saline and infused slowly over
15-30 minutes. For individuals over 10 kilograms body weight,
the desmopressin (DDAVP) is diluted in 50 ml of physiological
saline and for individuals less than 10 kilograms, 10 ml of
physiologic saline should be utilized. For more information,
refer to the product insert provided with desmopressin (DDAVP).
The new 4"' Edition of Hemostasis and Thrombosis will be published
in late 2000 and contains updated treatment recommendations.
